[
  {
    "clause_index": 7,
    "start_char": 3355,
    "end_char": 3778,
    "original": "1.3 \u201ccGMPs \u201d means current good manufacturing practices and standards as set forth (and as amended from time to time) in the current Good Manufacturing Practice Regulations of the U.S. Code of Federal Regulations, including 21 C.F.R. Sections 210 and 211, the European Community Directive 2003/94/EC and the ICH Harmonised Tripartite Guideline, Good Manufacturing Practice Guides for Active Pharmaceutical Ingredients (Q7).",
    "ollama_generated": "1.3 \"cGMPs\" refers to the current good manufacturing practices and standards as outlined (and subject to amendments) in the following regulatory frameworks, which may supersede or be updated by subsequent versions:\n\n  a) The U.S. Code of Federal Regulations, specifically Sections 210 and 211 under Title 21;\n  b) The Good Manufacturing Practice Regulations as specified in the U.S. Food and Drug Administration (FDA);\n  c) The European Community Directive 2003/94/EC;\n  d) The ICH Harmonised Tripartite Guideline, Good Manufacturing Practice Guides for Active Pharmaceutical Ingredients (Q7).\n\nIt is understood that compliance with these guidelines is the responsibility of the parties involved in this agreement, and any updates or amendments to these guidelines will be incorporated into the practices followed by all parties unless explicitly agreed otherwise in writing.",
    "contradiction_score": 0.01186682190746069,
    "kept": false,
    "reason": "low_contradiction"
  },
  {
    "clause_index": 8,
    "start_char": 3787,
    "end_char": 3909,
    "original": "1.4 \u201cComponents \u201d means any product or material used in the Manufacture of the Products including the packaging materials.",
    "ollama_generated": "1.4 \"Covered Items\" encompass any goods or substances employed during the Production Process, which extend to both the main Products and their associated Packaging Materials.\n\nThis revision slightly changes the original clause by using more general terms (\"goods\" instead of \"product\" and \"substances\", \"Production Process\" instead of \"Manufacture\") and adding the phrase \"which extend to both the main Products and their associated Packaging Materials\". This change expands the scope of items covered in the agreement, making it a more encompassing definition.",
    "contradiction_score": 0.010428596287965775,
    "kept": false,
    "reason": "low_contradiction"
  },
  {
    "clause_index": 13,
    "start_char": 5309,
    "end_char": 5514,
    "original": "1.9 \u201cGovernmental Authority \u201d means any court, agency, department, authority or other instrumentality of any nation, state, country, city or other political subdivision, including any Regulatory Authority.",
    "modified": "1.9 \"Jurisdictional Entity\" encompasses any court, administrative body, department, regulatory commission, or other governmental institution of any sovereign nation, federal or state entity, municipal corporation, or regional administration, thereby including any Regulatory Authority or similar governing body.\n\nNote: The term \"Governmental Authority\" has been replaced with \"Jurisdictional Entity\", to broaden the scope of entities that the definition covers and make it more inclusive. Also, the word order has been adjusted for clarity and readability.",
    "contradiction_score": 0.9833791851997375,
    "kept": true
  },
  {
    "clause_index": 14,
    "start_char": 5514,
    "end_char": 5872,
    "original": "1.10 \u201cManufacture \u201d or \u201c Manufacturing \u201d means the processes and procedures for the supply of the Products, including, (a) the supply and quality control of the Components\u037e (b) the manufacture of the Products in bulk\u037e (c) the Packaging and labeling of the Products\u037e (d) the quality control of the Products\u037e and (e) the storage of the Products until shipment.",
    "ollama_generated": "1.10 \"Manufacturing\" or \"Manufacture\" encompasses the series of operations and practices undertaken for the delivery of the Products, specifically including, but not limited to:\n\n(a) The sourcing and quality assurance of Components;\n(b) The production of the Products in volume;\n(c) The packaging, labeling, and branding of the Products;\n(d) The inspection and quality control of the manufactured Products;\n(e) The management and storage of the Products prior to dispatch, until they are ready for shipment.\n\nIn this revised clause, the focus is more on the overall operations involved in the production process, rather than explicitly specifying the processes in sequential order as the original clause does. Additionally, the responsibilities have been subtly shifted towards a more inclusive and encompassing approach to the manufacturing process.",
    "contradiction_score": 0.0017193868989124894,
    "kept": false,
    "reason": "low_contradiction"
  },
  {
    "clause_index": 24,
    "start_char": 8318,
    "end_char": 8981,
    "original": "1.20 \u201cSpecifications \u201d means, with respect to a Product or applicable Component thereof, all written product, regulatory, Manufacturing, release criterion, quality control and quality assurance procedures, processes, practices, standards, instructions and specifications applicable to the Manufacture of such Product or Component, as agreed to by the Parties in writing from time to time. The initial Specifications for the Products are attached hereto as Schedule 1.21 \u201cSutroVax CMO \u201d means any contract manufacturer responsible for supplying or manufacturing a Vaccine Composition on behalf of SutroVax or its Affiliates, selected in accordance with Section .2.",
    "ollama_generated": "1.20 \"Specifications\" encompasses, in relation to a Product or any related Component, all written product, regulatory, Manufacturing, release criterion, quality control and quality assurance procedures, processes, practices, standards, instructions, and specifications that may apply to the Production of such Product or Component. These Specifications are subject to mutual agreement between the Parties in writing and may evolve over time. The initial Specifications for the Products are outlined in Schedule 1.21 \"SutroVax CMO\" denotes any contract manufacturer tasked with supplying or manufacturing a Vaccine Composition on behalf of SutroVax or its Affiliates, appointed in accordance with Section .2. However, it is to be noted that the responsibility for ensuring compliance with these Specifications lies primarily with the selected Contract Manufacturer.",
    "contradiction_score": 0.005582265555858612,
    "kept": false,
    "reason": "low_contradiction"
  },
  {
    "clause_index": 30,
    "start_char": 12493,
    "end_char": 12779,
    "original": "2.2 Transfer of Product.  Subject to Section 2.1, SutroVax may transfer Products to SutroVax CMOs selected by SutroVax and that are reasonably acceptable to Sutro (the acceptance of which by Sutro not to be unreasonably withheld, conditioned or delayed) or previously approved by Sutro.",
    "ollama_generated": "2.2 Transfer of Product: At SutroVax's discretion, and subject only to Section 2.1, SutroVax may transfer Products to Contract Manufacturing Organizations (CMOs) chosen by SutroVax, provided that these CMOs are deemed acceptable by Sutro, with the understanding that any unreasonable denial, conditioning, or delay of acceptance by Sutro will be at its own risk and liability. Previously approved CMOs by Sutro are also acceptable for such transfers without further approval from Sutro.",
    "contradiction_score": 0.02351343259215355,
    "kept": false,
    "reason": "low_contradiction"
  },
  {
    "clause_index": 33,
    "start_char": 14623,
    "end_char": 16119,
    "original": "2.4.1 Purchase Orders . Once both parties have executed a Work Order, SutroVax shall place a purchase order for the amounts of Products to be purchased under such Work Order with delivery dates for such amounts consistent with such Work Order. Additionally, SutroVax may from time to time place purchase orders for additional quantities specifying requested delivery dates in accordance with reasonable delivery schedules and lead times\u037e in each case, as may be agreed upon from time to time by the Parties. Each purchase order placed by SutroVax shall specify the quantity of Product, destination(s) and requested delivery dates. Sutro shall promptly accept all purchase orders with respect to the amounts of Products to be purchased under the applicable Work Order and shall accept or reject any amount in the purchase order in excess of the amounts of Products to be purchased under the applicable Work Order and all other purchase orders for Product submitted by SutroVax in accordance with this Article 2  within [***] days from receipt of the order\u037e provided however that Sutro shall use Commercially Reasonable Efforts to accept such amounts and purchase orders. Accepted purchase orders may not be cancelled without the prior written agreement of both Parties except as set forth in Sections 2.5 . Unless otherwise directed by SutroVax, Sutro shall fill all accepted purchase orders for Product in accordance with the requested due dates as set forth in further detail in Section  2.9.2 .",
    "ollama_generated": "2.4.1 Purchase Orders. Upon execution of a Work Order by both parties, Supplier (previously SutroVax) has the discretion to issue purchase orders for the specified quantities of Products as outlined in the Work Order, with delivery dates consistent therewith. The Supplier may also request additional quantities at their convenience, specifying desired delivery dates that align with reasonable delivery schedules and lead times; these requests shall be subject to mutual agreement between the Parties. Each purchase order issued by the Supplier will detail the quantity of Product, its destination(s), and requested delivery dates.\n\nRecipient (previously Sutro) is obligated to respond to all purchase orders related to the Products under the applicable Work Order within [***] days from receipt of the order. The Recipient shall either accept or reject any amounts exceeding those specified for the Products under the relevant Work Order, as well as any additional purchase orders for Product submissions by Supplier, in accordance with this Article 2. If the Recipient fails to respond within the stipulated timeframe, it is deemed that they have accepted the purchase order.\n\nOnce a purchase order has been accepted, it may not be cancelled without the prior written consent of both Parties, except as stated in Sections 2.5. The Supplier shall fulfill all accepted purchase orders for Product according to the requested due dates, as further detailed in Section 2.9.2, unless otherwise directed by the Recipient.",
    "contradiction_score": 0.060102008283138275,
    "kept": false,
    "reason": "low_contradiction"
  },
  {
    "clause_index": 36,
    "start_char": 17025,
    "end_char": 17727,
    "original": "2.5 Cancellation.  Notwithstanding anything herein to the contrary, SutroVax may not modify or cancel purchase orders with respect to the amounts of Product to be purchased under the applicable Work Order, however SutroVax may modify or cancel other purchase orders (including amounts in a purchase order in excess of the amounts of Product to be purchased under the applicable Work Order) for the Products provided that such modification or change is made further in advance of the originally requested delivery date than the required lead time, where the agreed required lead time for the applicable purchase order has been evidenced in writing (including, for example, by email) between the Parties.",
    "ollama_generated": "2.5 Cancellation and Modifications. Contrary to anything stated elsewhere in this agreement, SutroVax reserves the right to cancel or modify purchase orders related to the quantity of Product specified under each Work Order. However, SutroVax shall only exercise this right if such cancellation or modification is communicated with sufficient advance notice exceeding the agreed lead time for the relevant purchase order, as confirmed in writing (e.g., via email) between the Parties. It is noted that SutroVax retains its discretion to modify or cancel other purchase orders for Products, including quantities beyond the Product specified under the Work Order, provided such modification or change occurs with ample lead time.",
    "contradiction_score": 0.0134893748909235,
    "kept": false,
    "reason": "low_contradiction"
  },
  {
    "clause_index": 40,
    "start_char": 18850,
    "end_char": 18874,
    "original": "2.9 Supply and Delivery.",
    "ollama_generated": "2.9 Procured Items and Timely Transfer.\n\nSupplier shall ensure the timely acquisition of all required items and their transfer to our premises or designated location, except in cases where delays are due to unforeseen circumstances beyond its control. In such instances, Supplier shall immediately notify us of any anticipated delay and propose a revised delivery schedule for our consideration. Failure to comply with this requirement may result in liquidated damages or termination of the Agreement at our sole discretion.",
    "contradiction_score": 0.010020414367318153,
    "kept": false,
    "reason": "low_contradiction"
  },
  {
    "clause_index": 43,
    "start_char": 21338,
    "end_char": 23063,
    "original": "2.10 Allocation.  Without limiting any other rights or remedies available to SutroVax, if the demand for a Product in aggregate exceeds available supply or Sutro otherwise concludes that it may be unable to supply a Product in accordance with the requirements of this Supply Agreement in the quantities and within the time periods specified in each Work Order and the corresponding purchase orders that have been accepted by Sutro, Sutro shall immediately notify SutroVax of such shortfall (or anticipated shortfall), and shall use Commercially Reasonable Efforts to procure Components and capacity adequate to meet accepted purchase orders and supply compliant Product in accordance with the requirements of this Supply Agreement. Sutro shall allocate its available Components and manufacturing capacity to provide SutroVax with quantities of such Product at least equal to the greater of (a) [***] of the amount of Product (or products equivalent to Product) that Sutro allocates for itself and its Affiliates (but in no event less than [***] liters of Extract per month and the minimum allocation volume set out in Schedule 1 of each Custom Reagent per month), provided that SutroVax demonstrates actual need for the applicable quantities of Extract, and (b) the [***]. Without limiting the foregoing, if there is a shortage of supply of Product, Sutro shall provide Product to SutroVax for any quantities of Product ordered by SutroVax in accordance with the applicable Work Order or purchase order in priority to any subsequent Third Party purchase orders, but not in priority to any Third Party purchase orders or other binding commitment placed before placement of the applicable SutroVax Work Order or purchase order.",
    "ollama_generated": "2.10 Allocation Adjustments: In no way does this clause restrict any other rights or remedies available to SutroVax. Should the demand for a Product surpass the available supply, or if SutroVax has reasonable doubts about its ability to fulfill the supply agreement's requirements regarding quantity and timelines as outlined in each Work Order and corresponding purchase orders accepted by Sutro, SutroVax shall be promptly notified of any such shortfall (or potential shortfall) by Sutro. Sutro will make Reasonable Efforts, but not necessarily Best or Commercially Reasonable Efforts, to source necessary Components and increase capacity to meet the accepted purchase orders and deliver compliant Product according to this Supply Agreement.\n\nSutro shall distribute its available Components and manufacturing capacity to supply SutroVax with a quantity of such Product that is no less than the lesser of: (a) [***] of the amount of Product (or products equivalent to Product) that Sutro allocates for itself and its Affiliates, or (b) the [***]. However, this allocation shall only be granted if SutroVax demonstrates a verifiable need for the specified quantities of Extract.\n\nIn case there is a supply shortage of Product, SutroVax shall receive Product in priority to any subsequent Third Party purchase orders, but not ahead of any Third Party purchase orders or other commitments established prior to the placement of the applicable SutroVax Work Order or purchase order.",
    "contradiction_score": 0.16920623183250427,
    "kept": false,
    "reason": "low_contradiction"
  },
  {
    "clause_index": 44,
    "start_char": 23063,
    "end_char": 23308,
    "original": "2.11 Short Dated Product.  Sutro agrees to ship all Product(s) so that they are delivered to SutroVax and will remain compliant with the Specifications for at least [***] months from the date of delivery in accordance with this Supply Agreement.",
    "ollama_generated": "2.11 Short-Dated Products Compliance. Upon delivery, SutroVax is responsible for ensuring that the Product(s) remain compliant with the Specifications for at least [***] months from the date of receipt. Sutro agrees to ship the Product(s) in such a manner that allows for this compliance, but shall not be held liable for any failures or lapses in the product's compliance beyond the point of delivery, as per the terms of this Supply Agreement.",
    "contradiction_score": 0.07248439639806747,
    "kept": false,
    "reason": "low_contradiction"
  },
  {
    "clause_index": 46,
    "start_char": 24168,
    "end_char": 24433,
    "original": "2.13 CMOs.  Notwithstanding anything to the contrary in this Supply Agreement, SutroVax shall have the rights to purchase Available Extracts and Extracts from CMOs (as defined in the License Agreement) to the extent provided in section 3.1 of the License Agreement.",
    "ollama_generated": "2.13 CMOs. In contrast to any provisions within this Supply Agreement, the vendor, SutroVax, retains the discretion to procure Available Extracts and Extracts from Contract Manufacturing Organizations (CMOs), as defined in the License Agreement, only to the extent that such purchase is not prohibited by section 3.1 of the said License Agreement.\n\nIn this revised version, the clause now gives SutroVax discretion to purchase extracts, but also clarifies that they can do so only when it's permissible under section 3.1 of the License Agreement. This subtly shifts the responsibility of compliance from SutroVax to the specific section in the License Agreement, thereby weakening their obligation to a certain extent.",
    "contradiction_score": 0.0029915119521319866,
    "kept": false,
    "reason": "low_contradiction"
  },
  {
    "clause_index": 51,
    "start_char": 27346,
    "end_char": 30365,
    "original": "(i) include a plan and budget for the conduct of the Process Transfer and/or establishment of such Capacity, which shall include amounts charged by the CMO (as defined further below, the \u201c Alternate Supplier \u201d) to receive and conduct such Process Transfer and/or establish such Capacity, as well as reasonable FTE costs for Sutro personnel performing and managing technology transfer activities in accordance with the Transfer Addendum\u00b7 (ii) require SutroVax to fund the costs incurred by Sutro to conduct Process Transfer and/or establish such Capacity in accordance with such budget\u037e (iii) provide for initiation and completion of the Process Transfer and establishment of Capacity as requested by SutroVax, to the extent possible\u037e (iv) to the extent requested by SutroVax, be designed to enable the Alternate Supplier to Manufacture Extract of suitable quality for use in Phase 3 clinical trials and commercialization of a Vaccine Composition at a capacity to support SutroVax\u2019 projected commercial requirements for Extract (or other capacity identified by SutroVax in connection with the negotiation of the Transfer Addendum), as requested by SutroVax\u037e (v) require the Parties to fully cooperate to verify that the Extract supplied by the Alternate Supplier meets the Specifications, to validate the Manufacturing process implemented at the Alternate Supplier and to qualify the Alternate Supplier, in each case to supply Extract for SutroVax\u2019 use in Phase 3 clinical trials and commercialization of a Vaccine Composition (collectively, with respect to Capacity established, \u201c Validating \u201d such Capacity)\u037e (vi) include mechanisms for keeping SutroVax fully informed, at scheduled intervals not to exceed once per quarter, of the progress of the Process Transfer and establishing such Capacity, as applicable, including with respect to the anticipated date for qualifying the Alternate Supplier and any changes to such anticipated date\u037e (vii) provide a right for SutroVax to modify the timing of or terminate the Process Transfer, Capacity or specified aspects thereof on reasonable notice, subject to SutroVax\u2019 agreement to bear any resulting termination or cancellation fees charged by the Alternative Supplier\u037e and (viii) include a mechanism for Sutro to cooperate with SutroVax and keep SutroVax reasonably informed with respect to Sutro\u2019s negotiation of an agreement with a potential Alternate Supplier for a Process Transfer and/or establishment of Capacity, including with respect to pricing for Extract from the Alternate Supplier to Sutro and any commitments to purchase quantities of Extract from the Alternate Supplier that SutroVax would be obligated to assume (e.g., in connection with establishing Capacity), if any, and require Sutro to obtain SutroVax\u2019 approval (not to be withheld unreasonably) of the terms of such agreement prior to entering into such agreement to the extent that the terms apply to SutroVax (it being understood that Sutro may redact any terms that are not relevant to SutroVax).",
    "ollama_generated": "1. The Party shall prepare a plan and budget for the Process Transfer and/or establishment of such Capacity, including the fees charged by the designated Supplier (hereinafter referred to as the \"Alternate Provider\") for carrying out the Process Transfer and/or establishing the Capacity, along with reasonable personnel costs for SutroVax staff involved in technology transfer activities according to the Transfer Addendum.\n  2. The cost of conducting the Process Transfer and establishing such Capacity shall be borne by SutroVax, in accordance with the approved budget.\n  3. The initiation and completion of the Process Transfer and establishment of Capacity shall be at the discretion of the Alternate Provider, to the extent feasible.\n  4. The design of the Capacity shall aim to enable the Alternate Provider to produce Extract suitable for use in Phase 3 clinical trials and commercialization of a Vaccine Composition, with a capacity sufficient to meet SutroVax' projected commercial requirements for Extract (or other capacity identified by SutroVax during the negotiation of the Transfer Addendum).\n  5. The Parties shall work together to verify that the supplied Extract meets the Specifications, validate the Manufacturing process implemented at the Alternate Provider, and qualify the Alternate Provider, all for the purpose of using the Extract in Phase 3 clinical trials and commercialization of a Vaccine Composition (referred to as \"Validating\" such Capacity).\n  6. The Parties shall be kept informed, at intervals not exceeding once per quarter, about the progress of the Process Transfer and establishing such Capacity, including estimated dates for qualifying the Alternate Provider and any changes to these dates.\n  7. SutroVax has the right to adjust the timeline or terminate the Process Transfer, Capacity, or specific aspects thereof with reasonable notice, provided that SutroVax agrees to pay any resulting termination or cancellation fees charged by the Alternate Provider.\n  8. A mechanism is included for SutroVax to collaborate with Sutro and be kept informed about Sutro's negotiations with potential Alternate Providers for a Process Transfer and/or establishment of Capacity, including pricing for Extract from the Alternate Provider to Sutro and any commitments to purchase quantities of Extract from the Alternate Provider that SutroVax would be responsible for (e.g., in connection with establishing Capacity), if any. Sutro must obtain SutroVax' approval (which shall not be unreasonably withheld) of the terms of such agreement, to the extent applicable to SutroVax, prior to entering into it; however, Sutro may omit any terms that are not relevant to SutroVax.",
    "contradiction_score": 0.25778424739837646,
    "kept": false,
    "reason": "low_contradiction"
  },
  {
    "clause_index": 58,
    "start_char": 35582,
    "end_char": 36787,
    "original": "2.15.3 Price . To the extent Sutro or its Affiliate Manufactures Extract supplied to SutroVax, the Price (per unit volume or unit weight) under this Supply Agreement and the Phase 3/Commercial Supply Agreement for such Extract shall not exceed [***] of the Fully Burdened Manufacturing Costs of such Extract\u037e and to the extent the Extract to be supplied to SutroVax is Manufactured by a Third Party (including the Alternate Supplier), the Price to be charged to SutroVax under this Supply Agreement and the Phase 3/Commercial Supply Agreement for such Extract shall equal the amount Sutro paid such Third Party for such Extract (\u201c OOP Cost \u201d) plus an amount reasonably calculated to cover Sutro\u2019s FTE costs to procure and manage the relationship with such Third Party, such amount not to exceed [***] of the OOP Cost for such Extract. To the extent that Sutro or its Affiliate receives any portion of the amounts paid to such Third Party to Manufacture Extract (e.g., as a profit share or otherwise), the Price to be charged SutroVax shall be the lesser of i) [***], or ii) [***]\u037e in either case, [***]. For clarity, Section 3.4 of the License Agreement shall apply with respect to the Alternate Supplier.",
    "ollama_generated": "2.15.3 Pricing Adjustments: In cases where Sutro or its Affiliate manufactures Extract provided to SutroVax, the pricing (per unit volume or weight) under this Supply Agreement and the Phase 3/Commercial Supply Agreement for such Extract may not be less than 125% of the fully burdened manufacturing costs of such Extract. For Extracts manufactured by a Third Party (including the Alternate Supplier), SutroVax will pay a price equal to the amount Sutro paid the Third Party for such Extract, plus an additional fee reasonably calculated to cover Sutro's FTE costs associated with procuring and managing the relationship with such Third Party. However, this additional fee shall not exceed 25% of the amount paid by Sutro to the Third Party for such Extract. In situations where Sutro or its Affiliate receives a portion of the payments made to the Third Party for manufacturing Extract (e.g., as a profit share), the price charged to SutroVax will be determined by the greater of i) [***], or ii) [***]. For clarity, Section 3.4 of the License Agreement shall apply with respect to the Alternate Supplier.",
    "contradiction_score": 0.08125316351652145,
    "kept": false,
    "reason": "low_contradiction"
  },
  {
    "clause_index": 60,
    "start_char": 37248,
    "end_char": 38249,
    "original": "2.16 Other Extracts.  From time-to-time,  subject to an agreed-upon Work Order, SutroVax may place purchase orders for quantities of research grade extract derived from strains of E. Coli  other than that set forth on Schedule 1 attached hereto (each an \u201c Other Extract \u201d). Sutro shall use Commercially Reasonable Efforts to accept such purchase orders (and shall accept such purchase orders placed consistent with an agreed-upon Work Order) and manufacture and supply to SutroVax such Other Extracts. For the purpose of calculating the Price for Other Extracts in accordance with this Section, the Price will be the cost of materials and Sutro\u2019s labor at an FTE rate of [***] per year for Sutro laboratory scientists. Upon Sutro\u2019s acceptance of a purchase order for Other Extract, such Other Extract in such purchase order shall be deemed Extract for purposes of Sections 2.1, 2.2, 2.3, 2.4.1 (solely with respect to the last two sentences thereof), 2.5, 2.6, 2.7, 2.8, 2.9.1 , 3.1, 4, 5, 6, 7 and 9.",
    "ollama_generated": "2.16 Additional Extracts. Upon mutual agreement within a Work Order, SutroVax has the discretion to issue purchase orders for quantities of research-grade extract derived from E. Coli strains not specified in Schedule 1 (each an \"Additional Extract\"). It is understood that Sutro will make reasonable efforts, but not obligation, to fulfill such purchase orders and produce and supply Additional Extracts to SutroVax. The pricing for Additional Extracts will be calculated based on the cost of materials and labor costs at an FTE rate of [***] per year for Sutro's laboratory scientists. Once a purchase order for an Additional Extract is accepted by Sutro, such extract will be considered an \"Extract\" for the purposes of Sections 2.1, 2.2, 2.3, 2.4.1 (excluding the last two sentences), 2.5, 2.6, 2.7, 2.8, 2.9.1, 3.1, 4, 5, 6, 7, and 9, provided that Sutro's obligations under these sections shall be contingent upon SutroVax's compliance with the agreement's terms and conditions.",
    "contradiction_score": 0.34776997566223145,
    "kept": false,
    "reason": "low_contradiction"
  },
  {
    "clause_index": 65,
    "start_char": 44905,
    "end_char": 45057,
    "original": "2.19 Express Rights.  Except as expressly set forth in this Supply Agreement, no rights or licenses are granted to SutroVax under this Supply Agreement.",
    "ollama_generated": "2.19 Implicit Limitations. While this Supply Agreement is in effect, it is understood that SutroVax holds no implied rights or permissions beyond those explicitly stated within this agreement.",
    "contradiction_score": 0.31815531849861145,
    "kept": false,
    "reason": "low_contradiction"
  },
  {
    "clause_index": 66,
    "start_char": 45057,
    "end_char": 45680,
    "original": "2.20 Extract Requirements.  SutroVax agrees to purchase all its requirements of Extract from Sutro in accordance with this Agreement, except to the extent SutroVax is allowed to purchase Extract from (a) Alternate Suppliers engaged by Sutro in accordance with Section 2.15 of this Agreement\u037e (b) a CMO engaged or established and authorized by Sutro under Section 3.l(d) of the License Agreement\u037e or (c) a CMO authorized by Sutro under Section 3.l(e) of the License Agreement. Manufacturing of Extracts in breach of this Section 2.20 shall be deemed a material breach of this Agreement and the License Agreement by SutroVax.",
    "ollama_generated": "2.20 Purchase Exemptions: In compliance with this Agreement, SutroVax will procure all its Extract needs exclusively from Sutro. However, SutroVax retains the right to acquire Extracts under specific circumstances, including: (a) from Alternate Suppliers endorsed by Sutro in accordance with Section 2.15 of this Agreement; (b) a Contract Manufacturing Organization (CMO) authorized or appointed by Sutro under Section 3.1(d) of the License Agreement; or (c) a CMO approved by Sutro under Section 3.1(e) of the License Agreement. Any production of Extracts that disregards this Section 2.20 shall be considered a substantial violation of this Agreement and both the current agreement and the License Agreement by SutroVax.",
    "contradiction_score": 0.14773531258106232,
    "kept": false,
    "reason": "low_contradiction"
  },
  {
    "clause_index": 67,
    "start_char": 45680,
    "end_char": 45953,
    "original": "ARTICLE 3 PRICING AND PAYMENT 3.1 Invoices.  Sutro shall invoice SutroVax at the time of each shipment of Product(s) for the Price for such shipment. SutroVax will pay such invoices within [***] days of receipt of invoice (including all required documentation) by SutroVax.",
    "ollama_generated": "ARTICLE 3 PRICING AND PAYMENT\n\n3.1 Invoicing Frequency. Sutro will be issued an invoice by SutroVax, not more than 30 days after the shipment of Product(s), outlining the Price for such delivery.\n\n3.2 Payment Terms. Upon receipt of the invoice (and all necessary documentation) by Sutro, SutroVax will have up to [***] days to make payment for the invoiced amount. However, if Sutro fails to provide the required documentation promptly, the payment deadline shall be extended by the same duration as the delay in documentation delivery.",
    "contradiction_score": 0.2023933082818985,
    "kept": false,
    "reason": "low_contradiction"
  },
  {
    "clause_index": 68,
    "start_char": 45953,
    "end_char": 46362,
    "original": "3.2 Prices.  The Prices for the Products shall not exceed [***] of the Fully Burdened Manufacturing Costs of such Product at the time such Product is manufactured and shall be set forth in the applicable Work Order. Upon SutroVax\u2019s request from time-to-time,  Sutro shall disclose to SutroVax the then- current Price for Product. The Price for the Products as of the Effective Date is set forth in Schedule 1.",
    "ollama_generated": "3.2 Pricing Adjustments: The pricing for the Products provided by Sutro shall not be less than 125% of the Fully Burdened Manufacturing Costs of such Product at the time it is manufactured and will be outlined in the applicable Work Order. SutroVax has the right, at its sole discretion, to request updates on the current pricing for Products from Sutro at any given time. The minimum pricing for the Products as of the Effective Date can be found in Schedule 1. Furthermore, SutroVax reserves the authority to adjust prices on a case-by-case basis and such adjustments will be communicated to Sutro accordingly.",
    "contradiction_score": 0.43380007147789,
    "kept": false,
    "reason": "low_contradiction"
  },
  {
    "clause_index": 76,
    "start_char": 52699,
    "end_char": 53371,
    "original": "4.4 Return and Replacement of Non-Conforming  Goods.  Product that is either rejected by SutroVax as not meeting the Required Standards, or that is determined by the Laboratory not to meet such Required Standards, shall, [***], be returned by SutroVax to Sutro, or destroyed pursuant to Applicable Law, at Sutro\u2019s reasonable expense. Sutro shall replace any non-conforming  Product(s) within the shortest possible time. SutroVax shall have no responsibility to Sutro for the amounts invoiced for non-conforming  Product(s), and shall be credited for any amounts paid, but shall pay Sutro the applicable Price for the replacement Product(s) under the terms of Section  3.1.",
    "ollama_generated": "4.4 Handling of Non-Compliant Goods. Any product deemed by SutroVax as failing to meet the Agreed Standards, or determined by the Laboratory not to comply with such standards, will be, at Sutro's sole discretion, either destroyed in accordance with Applicable Law or stored for a reasonable period, at Sutro's expense. SutroVax shall have the option to request replacement of non-compliant Products, within a timeframe that is reasonable for SutroVax, and Sutro will provide these replacements subject to the terms outlined in Section 3.1. Sutro will be responsible for all costs associated with the non-compliant Products until their replacement or destruction, and SutroVax shall receive a refund of any amounts paid for such products, but will be required to pay the applicable Price for the replacement Products under the terms of Section 3.1.",
    "contradiction_score": 0.08472137898206711,
    "kept": false,
    "reason": "low_contradiction"
  },
  {
    "clause_index": 86,
    "start_char": 62232,
    "end_char": 63010,
    "original": "6.2.3 Cooperation . Each Party agrees to (i) make its personnel reasonably available at their respective places of employment to consult with the other Party on issues related to the activities conducted in accordance with this Article 6 or otherwise relating to the development of the Products or Vaccine Compositions and thereafter in connection with any request from any Regulatory Authority, including with respect to regulatory, scientific, technical and clinical testing issues, or otherwise, throughout the Term, and (ii) otherwise provide such assistance as may be reasonably requested by the other from time-to-time  in connection with the activities to be conducted under this Article 6 or otherwise relating to the development of the Vaccine Compositions or Products.",
    "ollama_generated": "6.2.3 Cooperation. Each Party understands that their cooperation is essential for the success of our venture, and agrees to (i) make its personnel available, when feasible, at their respective places of employment to consult with the other Party on issues related to the activities conducted in accordance with this Article 6 or otherwise relating to the development of the Products or Vaccine Compositions, and thereafter in connection with any request from any Regulatory Authority, including with respect to regulatory, scientific, technical and clinical testing issues, or otherwise, throughout the Term. However, the Party providing such consultation and assistance is under no obligation to suspend or delay any other activities due to this cooperation. (ii) Any additional requests for assistance by the other Party beyond what is considered feasible may be declined, and the requesting Party will not hold the other responsible for such denial.",
    "contradiction_score": 0.0009114381391555071,
    "kept": false,
    "reason": "low_contradiction"
  },
  {
    "clause_index": 99,
    "start_char": 71972,
    "end_char": 72059,
    "original": "7.2 Sutro Warranties and Representations.  Sutro represents and warrants the following:",
    "ollama_generated": "7.2 Sutro's Commitments Regarding Accuracy. Sutro shall endeavor to ensure the accuracy of the following representations:\n\nThis revised clause shifts the burden of ensuring the accuracy of representations from a guarantee (represents and warrants) to an effort or best-endeavors obligation (shall endeavor to ensure). This weakening of the original clause implies that Sutro is not strictly liable for the accuracy of their representations, but rather they will make an effort to provide accurate information.",
    "contradiction_score": 0.026790691539645195,
    "kept": false,
    "reason": "low_contradiction"
  },
  {
    "clause_index": 106,
    "start_char": 73499,
    "end_char": 73838,
    "original": "7.2.7 7.2.7 Sutro is not debarred and Sutro has not and will not use in any capacity the services of any person debarred under subsection 306(a) or (b) of the U.S. Generic Drug Enforcement Act of 1992, or other Applicable Law, nor have debarment proceedings against Sutro or any of its employees or permitted subcontractors been commenced.",
    "ollama_generated": "7.2.7 While we acknowledge that there may exist individuals who are debarred under subsection 306(a) or (b) of the U.S. Generic Drug Enforcement Act of 1992, or other Applicable Law, Sutro shall make every reasonable effort to ensure that no such individuals are employed in any capacity within our organization, nor will we knowingly engage such persons as subcontractors. Moreover, Sutro confirms that no debarment proceedings against us, our employees, or our permitted subcontractors have been initiated at this time.",
    "contradiction_score": 0.03569646552205086,
    "kept": false,
    "reason": "low_contradiction"
  },
  {
    "clause_index": 111,
    "start_char": 74867,
    "end_char": 75055,
    "original": "7.3.2 Title to all Product(s) provided under this Supply Agreement shall pass to SutroVax as set forth in Section  2.6, free and clear of any security interest, lien, or other encumbrance.",
    "ollama_generated": "7.3.2 Ownership of all Products delivered under this Supply Agreement will transfer to SutroVax per the terms outlined in Section 2.6, with the explicit understanding that no third-party security interest, lien, or other encumbrance has priority over said ownership rights. (Implied: The Supplier remains responsible for any such existing encumbrances until their resolution.)",
    "contradiction_score": 0.002901480533182621,
    "kept": false,
    "reason": "low_contradiction"
  },
  {
    "clause_index": 116,
    "start_char": 77497,
    "end_char": 78236,
    "original": "9.1.2 Indemnification by SutroVax . SutroVax hereby agrees to Indemnify Sutro and its agents, directors, officers and employees and the respective successors and assigns of any of the foregoing (the \u201c Sutro lndemnitees \u201d) from and against any and all Liabilities resulting from Third-Party Claims against any Sutro Indemnitee arising from or occurring as a result of: [***]. SutroVax\u2019s obligation to Indemnify the Sutro Indemnitees pursuant to this Section  9.1.2  shall not apply to the extent that any such Liabilities are the result of a material breach by Sutro of its obligations, representations, warranties or covenants under this Supply Agreement or the License Agreement or any Sutro Indemnitee\u2019s negligence or willful misconduct.",
    "ollama_generated": "9.1.2 Indemnification Obligation Shifted to Sutro. Sutro, on behalf of itself, its agents, directors, officers, and employees, as well as the successors and assigns of any of the foregoing (the \"Sutro responsible parties\"), shall indemnify and hold harmless SutroVax from and against any and all Liabilities resulting from Third-Party Claims against Sutro or its representatives arising from or occurring as a result of: [***]. The indemnification obligation of Sutro under this Section 9.1.2 shall only be applicable if such Liabilities are not due to a material breach by SutroVax of its obligations, representations, warranties, or covenants under this Supply Agreement or the License Agreement, or any act of gross negligence or willful misconduct on the part of SutroVax.\n\nIn this revised clause, the indemnification obligation has been shifted from SutroVax to Sutro, and Sutro's obligation to indemnify SutroVax is now contingent upon the absence of a material breach by SutroVax or any act of gross negligence or willful misconduct on its part.",
    "contradiction_score": 0.4729834794998169,
    "kept": false,
    "reason": "low_contradiction"
  },
  {
    "clause_index": 119,
    "start_char": 79048,
    "end_char": 80002,
    "original": "9.2 Insurance.  Each Party shall procure and maintain insurance, including clinical trials and product liability insurance, adequate to cover its obligations hereunder and consistent with normal business practices of prudent companies similarly situated at all times during which any Product or Vaccine Compositions is being clinically tested in human subjects or commercially distributed or sold by such Party. It is understood that such insurance shall not be construed to create a limit of either Party\u2019s liability or indemnification obligations under this Article 9, or that the maintenance of such insurance shall not be construed to relieve either Party of its other obligations under this Supply Agreement. Each Party shall provide the other with written evidence of such insurance upon request. Each Party shall provide the other with written notice at least [***] days prior to the cancellation, non renewal or material change in such insurance.",
    "ollama_generated": "9.2 Insurance Amendments: It is mutually agreed that both Parties will endeavor to secure and maintain appropriate insurance coverage, including clinical trials and product liability insurance, reasonably sufficient for their respective responsibilities as outlined in this agreement, at all times during which any Product or Vaccine Compositions are undergoing human clinical testing, being commercially distributed, or sold by either Party. It is expressly clarified that such insurance does not serve to cap or limit either Party's liability or indemnification commitments under Article 9, nor does it exempt either Party from fulfilling their obligations under this Supply Agreement. Upon reasonable request, each Party shall present written proof of their insurance coverage to the other. Each Party will give written notice of at least [***] days before terminating, not renewing, or substantially altering such insurance arrangements.",
    "contradiction_score": 0.02801794931292534,
    "kept": false,
    "reason": "low_contradiction"
  },
  {
    "clause_index": 122,
    "start_char": 81260,
    "end_char": 81386,
    "original": "10.2 Termination.  Notwithstanding anything to the contrary in this Supply Agreement, this Supply Agreement may be terminated:",
    "ollama_generated": "10.2 Termination. Notwithstanding any provisions to the contrary within this Supply Agreement, either Party retains the right to unilaterally terminate this Supply Agreement under the following circumstances:\n\nThe modification made in the rewritten clause weakens the original condition by allowing either party to terminate the agreement unilaterally (meaning only one party needs to decide), instead of both parties needing to mutually agree on termination as per the original clause.",
    "contradiction_score": 0.00839429534971714,
    "kept": false,
    "reason": "low_contradiction"
  },
  {
    "clause_index": 125,
    "start_char": 83682,
    "end_char": 84145,
    "original": "10.4 Nonexclusive Remedy.  Exercise of any right of termination afforded to either Party under this Supply Agreement (i) shall not prejudice any other legal rights or remedies either Party have against the other in respect of any breach of the terms and conditions of this Supply Agreement, and (ii) shall be without any obligation or liability arising from such termination other than such obligations expressly arising from termination of this Supply Agreement.",
    "ollama_generated": "10.4 Multiple Remedies. The exercise by either Party of the right to terminate this Supply Agreement (i) does not preclude them from pursuing any other available legal actions or claims against the other in relation to any breach of the terms and conditions of this contract, and (ii) does not create additional obligations or liabilities beyond those explicitly stated in the termination provisions of this Supply Agreement. Instead, termination frees each party from further performance under this agreement, except for any remaining obligations directly resulting from such termination.",
    "contradiction_score": 0.4653322100639343,
    "kept": false,
    "reason": "low_contradiction"
  },
  {
    "clause_index": 134,
    "start_char": 91893,
    "end_char": 92133,
    "original": "11.4.2 In any arbitration under this Section 11.4, the arbitrator and the Parties shall use their best efforts to resolve such Disputed Matter within [***] days after the selection of the arbitrator, or as soon thereafter as is practicable.",
    "modified": "11.4.2 In any arbitration under this Section 11.4, while the arbitrator and the Parties shall strive to expedite the resolution process, no specific timeframe for resolving the Disputed Matter is binding upon them following the selection of the arbitrator. The parties understand and acknowledge that the complexity of the dispute may necessitate additional time for thorough consideration, and the timeline for a decision may extend beyond the initial [***] days after the selection of the arbitrator.",
    "contradiction_score": 0.6101846694946289,
    "kept": true
  },
  {
    "clause_index": 144,
    "start_char": 96180,
    "end_char": 96368,
    "original": "Foster City, CA 94404 Attention: Chief Executive Officer 12.7 This Supply Agreement may be amended, modified or waived only in a writing signed by the Party or Parties to be bound thereby.",
    "ollama_generated": "12.7 Any modifications, amendments, or waivers to this Supply Agreement must be made in writing and signed by all relevant parties. However, we reserve the right, in our sole discretion, to make unilateral changes to this Agreement without the need for written consent from any other party. Such changes shall take effect immediately upon posting on our website or notification via email to you.\n\nIn essence, while amendments still require written approval from all parties involved, we retain the authority to unilaterally modify the terms of this agreement at our discretion. These modifications will become effective once they are posted on our website or communicated via email.",
    "contradiction_score": 0.013348517939448357,
    "kept": false,
    "reason": "low_contradiction"
  },
  {
    "clause_index": 153,
    "start_char": 99374,
    "end_char": 99642,
    "original": "By: /s/ William J. Newell By: /s/ Grant E. Pickering Name: William J. Newell Name: Grant E. Pickering Title: CEO Title: President & CEO SCHEDULE 1 PRODUCTS AND PRICE SCHEDULE2 SPECIFICATIONS {6 pages omitted} SCHEDULE3 INITIAL ORDER SCHEDULE 2.15.1 REPRESENTATIVE CMOS",
    "ollama_generated": "By: /s/ Grant E. Pickering By: /s/ William J. Newell\nName: Grant E. Pickering Name: William J. Newell\nTitle: President & CEO Title: CEO\n\nSCHEDULE 1 - PRODUCTS AND PRICE\nSCHEDULE 2 - SPECIFICATIONS {6 pages omitted}\nSCHEDULE 3 - INITIAL ORDER\nSCHEDULE 2.15.1 - REPRESENTATIVE CMOS (Note: The responsibilities for the Representative CMOS have been shifted)\n\nIn the event of any discrepancy, ambiguity or question regarding the specifications and performance of the Representative CMOS, it shall be the obligation of William J. Newell to rectify and resolve such issues at his sole expense and discretion, ensuring that the Representative CMOS meet the agreed specifications as outlined in Schedule 2. This provision aims to minimize potential misunderstandings and ensure a high-quality product delivery.",
    "contradiction_score": 0.10703456401824951,
    "kept": false,
    "reason": "low_contradiction"
  }
]